Cohen Steven P, Strassels Scott A, Foster Leslie, Marvel John, Williams Kayode, Crooks Matthew, Gross Andrew, Kurihara Connie, Nguyen Cuong, Williams Necia
Department of Anesthesiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
BMJ. 2009 Apr 14;338:b1088. doi: 10.1136/bmj.b1088.
To determine whether fluoroscopic guidance improves outcomes of injections for greater trochanteric pain syndrome.
Multicentre double blind randomised controlled study.
Three academic and military treatment facilities in the United States and Germany.
65 patients with a clinical diagnosis of greater trochanteric pain syndrome.
Injections of corticosteroid and local anaesthetic into the trochanteric bursa, using fluoroscopy (n=32) or landmarks (that is, "blind" injections; n=33) for guidance.
0-10 numerical rating scale pain scores at rest and with activity at one month (positive categorical outcome predefined as >or=50% pain reduction either at rest or with activity, coupled with positive global perceived effect). Secondary outcome measures included Oswestry disability scores, SF-36 scores, reduction in drug use, and patients' satisfaction.
No differences in outcomes occurred favouring either the fluoroscopy or blind treatment groups. One month after injection the average pain scores were 2.7 at rest and 5.0 with activity in the fluoroscopy group compared with 2.2 and 4.0 in the blind injection group. Three months after the injection, 15 (47%) patients in the blind group and 13 (41%) in the fluoroscopy group continued to have a positive outcome.
Although using fluoroscopic guidance dramatically increases treatment costs for greater trochanteric pain syndrome, it does not necessarily improve outcomes.
Clinical trials NCT00480675.
确定透视引导是否能改善大转子疼痛综合征注射治疗的效果。
多中心双盲随机对照研究。
美国和德国的三家学术及军事治疗机构。
65例临床诊断为大转子疼痛综合征的患者。
向转子囊内注射皮质类固醇和局部麻醉剂,使用透视引导(n = 32)或体表标志引导(即“盲注”;n = 33)。
1个月时静息和活动时的0 - 10数字评分量表疼痛评分(预先定义阳性分类结局为静息或活动时疼痛减轻≥50%,同时伴有总体感觉良好)。次要结局指标包括奥斯威斯功能障碍评分、SF - 36评分、药物使用减少情况及患者满意度。
透视组和盲注组在结局方面无差异。注射1个月后,透视组静息时平均疼痛评分为2.7,活动时为5.0;盲注组静息时为2.2,活动时为4.0。注射3个月后,盲注组15例(47%)患者和透视组13例(41%)患者仍有阳性结局。
尽管使用透视引导会显著增加大转子疼痛综合征的治疗成本,但不一定能改善治疗效果。
临床试验NCT00480675。